2PQ Stock Chart & Stats
€1.48
€0.02(0.91%)
At close: 4:00 PM EDT
€1.48
€0.02(0.91%)
Day’s Range― - ―
52-Week Range€1.25 - €5.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€165.47M
Enterprise Value€472.65
Total Cash (Recent Filing)€46.10M
Total Debt (Recent Filing)€66.95M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding128,674,550
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.73Price Target Upside16.63% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)€167.70M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence Supports Product AdoptionPositive randomized and real-world evidence can strengthen physician confidence, payer discussions, and repeat utilization of Organogenesis products. A broader clinical foundation may support durable differentiation in advanced wound care and improve the company’s ability to defend or regain market share.
Significant Cost-reduction ProgramThe restructuring program provides a tangible path to a lower operating-cost base, including savings from the 138-employee reduction and additional planned quarterly reductions. If revenue stabilizes, these actions could materially improve operating leverage and reduce recurring losses.
Debt-free Balance Sheet And Funding RunwayNo outstanding debt limits interest burden and near-term refinancing pressure while preserving flexibility to fund operations and selected growth initiatives. Management’s stated 12-month funding expectation gives the company time to execute its recovery plan, although cash levels remain important to monitor.
Bears Say
Severe Revenue ContractionThe sharply reduced revenue outlook indicates that the business is facing a substantial demand and market reset rather than a modest cyclical slowdown. Persistent top-line contraction can weaken commercial scale, reduce fixed-cost absorption, and delay a return to sustainable profitability.
Margin And Earnings DeteriorationThe collapse in gross margin, combined with a much larger operating and net loss, shows that current revenue levels are not supporting the prior earnings structure. Margin recovery will depend on improved volume, product mix, and execution, making the profitability reset a durable fundamental risk.
Cash Depletion And Dilution RiskThe sharp cash reduction increases sensitivity to continued losses and execution delays, even with management’s stated funding runway. Reliance on an ATM facility creates potential shareholder dilution and signals that external capital may be needed if product cash flows do not recover as planned.
Organogenesis Holdings News
2PQ FAQ
What was Organogenesis Holdings Inc’s price range in the past 12 months?
Organogenesis Holdings Inc lowest stock price was €1.25 and its highest was €5.75 in the past 12 months.
What is Organogenesis Holdings Inc’s market cap?
Organogenesis Holdings Inc’s market cap is €165.47M.
When is Organogenesis Holdings Inc’s upcoming earnings report date?
Organogenesis Holdings Inc’s upcoming earnings report date is Nov 05, 2026 which is in 51 days.
How were Organogenesis Holdings Inc’s earnings last quarter?
Organogenesis Holdings Inc released its earnings results on Aug 06, 2026. The company reported -€0.611 earnings per share for the quarter, missing the consensus estimate of -€0.3 by -€0.312.
Is Organogenesis Holdings Inc overvalued?
According to Wall Street analysts Organogenesis Holdings Inc’s price is currently Undervalued.
Does Organogenesis Holdings Inc pay dividends?
Organogenesis Holdings Inc does not currently pay dividends.
What is Organogenesis Holdings Inc’s EPS estimate?
Organogenesis Holdings Inc’s EPS estimate is -0.15.
How many shares outstanding does Organogenesis Holdings Inc have?
Organogenesis Holdings Inc has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings Inc’s price movement after its last earnings report?
Organogenesis Holdings Inc reported an EPS of -€0.611 in its last earnings report, missing expectations of -€0.3. Following the earnings report the stock price went down -22.598%.
Which hedge fund is a major shareholder of Organogenesis Holdings Inc?
Currently, no hedge funds are holding shares in DE:2PQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.73 (16.63% Upside)
€1.73 (16.63% Upside)
Blogger Sentiment
Bullish
DE:2PQ Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Organogenesis Holdings Inc
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
2PQ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.View all DE:2PQ earnings summaries2PQ Stock 12 Month Forecast
Average Price Target
€1.73
▲(16.63% Upside)